The full-length major capsid protein, VP1, of the human polyomavirus JC virus was cloned and expressed in Escherichia coli. VP1 protein expressed in E. coli self-assembled into capsid-like particles and caused haemagglutination of human O-type red blood cells. Caesium chloride density-gradient centrifugation analysis revealed that the capsid-like particles consisted of virionlike pseudovirion and empty capsid-like pseudocapsid populations. The morphology of pseudovirion and pseudocapsid particles was observed under the electron microscope. The pseudovirions contained DNA and RNA molecules but the pseudocapsids did not contain any nucleic acid, as analysed by DNA extraction. DNA-binding activity of VP1 was also demonstrated by the SouthWestern probing method in vitro. Furthermore, pseudocapsids were able to deliver exogenous DNA into human foetal kidney epithelial cells. These results indicate that recombinant JC virus VP1 is able to self-assemble into capsid-like particles and to package DNA in the absence of the minor capsid proteins, VP2 and VP3. This prokaryotic assembly system may facilitate the investigation of maturation mechanism(s) of polyomaviruses. Furthermore, capsid-like particles of JC virus VP1 generated in E. coli potentially could be used as a human gene transfer vector.
Introduction
Human JC virus (JCV) is a member of the genus Polyomavirus, which includes murine polyomavirus, simian virus 40 (SV40), human BK virus (BKV) and other animal polyomaviruses (Tooze, 1981) . It has been demonstrated that JCV can transform human amnion cells (Howley et al., 1980) and foetal brain cells (Mandl et al., 1987) in vitro and induce various tumours in other animals (reviewed in Zu Rhein, 1983) . Transformation and tumour induction may be due to interaction between the large tumour antigen of JCV and the cellular retinoblastoma protein (Dyson et al., 1990) and p53 protein (Mandl & Frisque, 1986) . JCV can cause progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease, in immunocompromised individuals (Padgett et al., Author for correspondence : Deching Chang.
Fax j886 4 3847178. e-mail dch!mercury.csmc.edu.tw 1976 ; Walker & Frisque, 1986 ; White et al., 1992) . PML is the result of JCV lytic infection of oligodendrocytes (Walker & Frisque, 1986) .
Few studies have focused on the lytic infection pathway of JCV, partly because of the difficulty of propagating the virus in cell culture (Feigenbaum et al., 1987) . The JCV virion contains three capsid proteins (VP1, VP2 and VP3) and a viral minichromosome (Walker & Frisque, 1986 ). VP1 is the major capsid protein of JCV, constituting approximately 75 % of the capsid shell protein, while VP2 and VP3 are the minor capsid proteins that make up about 10 % of the capsid proteins (Tooze, 1981) . X-ray crystallography of murine polyomavirus (Griffith et al., 1992 ; Rayment et al., 1982) and SV40 (Liddington et al., 1991) has demonstrated that the polyomavirus capsid shell consists of 12 pentavalent and 60 hexavalent capsomeres in a T l 7 icosahedral surface lattice. Five VP1 molecules form a pentameric capsomere. Minor capsid proteins VP2 and\or VP3 extend from the core into the axial cavity of the VP1 pentamers (Griffith et al., 1992 ; Rayment et al., 1982) .
The mechanism of virion assembly and maturation in polyomavirus progeny formation during lytic infection has been extensively investigated. In previous studies, the structural proteins of murine polyomavirus (Forstova et al., 1993 ; Gillock et al., 1997 ; Montross et al., 1991) , SV40 (Kosukegawa et al., 1996) , monkey B-lymphotropic papovavirus (BLPV) (Pawlita et al., 1996) and JCV (Chang et al., 1997) have been expressed in insect cells in order to analyse their structural properties. These studies have shown that the major capsid protein, VP1, of polyomaviruses is able to self-assemble into capsid-like particles when expressed in insect cells (Chang et al., 1997 ; Forstova et al., 1993 ; Gillock et al., 1997 ; Kosukegawa et al., 1996 ; Montross et al., 1991 ; Pawlita et al., 1996) . Furthermore, VP1 from murine polyomavirus (Salunke et al., 1986) , avian polyomavirus, budgerigar fledgling disease virus (BFDV) (Rodgers et al., 1994) and the L1 capsid protein of papillomavirus (Li et al., 1997) have also been expressed in E. coli and isolated as pentameric capsomeres. Although capsomeres isolated from E. coli could be assembled into a capsid-like structure in the presence of calcium ions in vitro, self-assembly in E. coli of capsid-like particles made up of major capsid proteins has not been reported. The current study showed that JCV VP1 was able to self-assemble into capsid-like particles in E. coli cells. In addition, these particles were composed of pseudovirion and empty pseudocapsid populations. Host DNA and RNA molecules were encapsidated in the pseudovirion particles. This pseudovirion assembly in E. coli may provide a convenient model for investigating the mechanism of polyomavirus progeny maturation and may lead to the development of a human gene transfer vector.
Methods
Construction and expression of the JCV VP1 gene. The VP1 gene of JCV has been cloned previously into a prokaryotic expression vector, pGEX-4T-1, to generate pGEXJCV1 and to express a GST-VP1 fusion protein (Chang et al., 1996 a) . In this study, the VP1 gene was excised from pGEXJCV1 by digesting the plasmid with BamHI. The VP1 fragment was then ligated with the BglII-digested prokaryotic expression vector ∆pFlag to generate ∆pFJCV1. ∆pFlag was derived from pFlag-1 (IBI) by digestion with NdeI and SalI to delete the fusion portion, as previously described . This construct was made to allow expression of a non-fusion, full-length VP1 protein. The VP1-expressing plasmid, ∆pFJCV1, was used to transform E. coli JM109 cells. Authentic VP1 protein expression was induced at an early exponential phase by the addition of 0n5 mM (final concentration) IPTG for 4 h at 30 mC.
Purification of JCV capsid-like particles. E. coli JM109 cells expressing JCV VP1 protein were grown in LB medium and harvested by centrifugation at 4000 g for 10 min. The cell pellet was resuspended in 10 mM Tris-HCl, pH 7n4, 150 mM NaCl and lysozyme (Calbiochem) was added to a final concentration of 1 mg\ml. After incubation for 30 min at 4 mC, protease inhibitors (aprotinin, N-tosyl--lysine chloromethyl ketone, N-tosyl--phenylalanine chloromethyl ketone and PMSF, each at 10 µg\ml) were added. The cells were then lysed by five cycles of sonication in 30 s bursts. The total lysate was treated with DNase I (200 U\ml) for 45 min at 25 mC and then centrifuged at 16 500 g for 20 min. The supernatant, which contained the soluble form of VP1, was analysed by haemagglutination assay, haemagglutination inhibition assay, SDS-PAGE and Western blot.
To purify capsid-like particles, the supernatant was subjected to 20 % sucrose cushion centrifugation at 35 000 r.p.m. for 3 h in an SW-41 Ti rotor (Beckman). The pellet, containing the partially purified capsid-like particles, was resuspended in 0n5 ml 10 mM Tris-HCl, pH 7n4, 150 mM NaCl and sonicated five times in 15 s bursts to disrupt aggregates. The suspension was layered onto a pre-set five-step CsCl gradient (1n35, 1n32, 1n29, 1n25 and 1n20 g\cm$) and centrifuged at 33 000 r.p.m. for 36 h in a Beckman SW-55 Ti rotor. Fractions, each containing 125 µl, were collected and analysed for HA activity and buoyant density distribution.
Haemagglutination (HA) assay and HA inhibition assay. Aliquots (5 µl) of E. coli lysate containing JCV VP1 protein or of fractions from CsCl gradient centrifugation were mixed with 0n5 % O-type human red blood cells in a serial two-fold dilution for HA assay. To determine HA inhibition, 28 µl JCV-positive or -negative human serum (Chang et al., 1996 b) was incubated for 30 min at 56 mC followed by the addition of 14 µl 0n1 M NaIO % and incubation for 30 min at room temperature. After the incubation, 14 µl PBS containing 5 % glycerol was added. Twenty-five µl serum mixture was used to react with 25 µl E. coli lysate containing JCV VP1 protein for 1 h at 37 mC. Fifty µl O-type human red blood cells (0n5 %) was then added. The mixture was incubated for 2 h at room temperature and read for HA inhibition.
Electrophoresis and Western blot analysis. Total E. coli protein containing JCV VP1 protein and CsCl-purified VP1 capsid-like particles were resolved by 12n5 % SDS-PAGE and visualized by Coomassie blue staining as previously described (Ausubel et al., 1987) . For Western blot, proteins in the SDS-PAGE gel were electro-transferred onto a nitrocellulose membrane (MSI) with a semi-dry system (Atto, Tokyo). The membrane was blocked with 5 % non-fat milk in 50 mM Tris-HCl, pH 7n4, 150 mM NaCl and reacted with 1 : 3000 diluted rabbit JCV-VP1 antiserum (Chang et al., 1996 a) . Biotin-conjugated goat antirabbit antibody and horseradish peroxidase-conjugated avidin (Vector) were used to detect VP1 protein.
Electron microscopy of capsid-like particles. CsCl-purified recombinant capsid-like particles were mounted on formvar-coated grids and stained with 2 % uranyl acetate. Specimens were examined with a JEOL 2000-CX electron microscope, operating at 80 kV.
Nucleic acid extraction from capsid-like particles. To analyse the nucleic acids encapsidated in capsid-like particles, 45 µg CsCl-purified capsid-like particles were treated with proteinase K (final concentration 200 µg\ml), 1 % SDS and 25 mM EDTA at 37 mC for 30 min. An equal volume of phenol-chloroform was added to extract nucleic acids (Hirt, 1967) . The mixture was then centrifuged at 12 000 r.p.m. for 5 min. The aqueous phase was mixed with sodium acetate (final concentration 0n3 M). Three vols cold ethanol was added to precipitate nucleic acids. After incubation at k20 mC for 3 h, nucleic acids were pelleted by centrifugation at 14 000 r.p.m. for 15 min at 4 mC. The pellet was then resuspended in 50 µl distilled water. To distinguish DNA and RNA molecules encapsidated in capsid-like particles, 10 µl nucleic acid extract was treated with DNase I (final concentration 0n01 mg\ml) (Sigma) at 37 mC for 10 min or with RNase A (final concentration 0n5 µg\ml) (Sigma) at 37 mC for 45 min. Nucleic acids with or without nucleases were analysed on 1 % agarose gels as previously described (Ausubel et al., 1987) .
In vitro DNA-binding assay. E. coli cell lysate containing VP1 protein was electro-transferred onto a nitrocellulose membrane after SDS-PAGE. The membrane was incubated with 10 mM Tris-HCl, pH 6n7, 50 mM NaCl, 1 mM EDTA containing 1iDenhardt's solution (Sigma) for 30 min at 22 mC for blocking and renaturing Clever et al., 1992 ; . JCV genomic DNA (GenBank accession no. U61771) (Ou et al., 1997) or pGEM-7 plasmid DNA was nick-translated with [α-$#P]dATP (Amersham) (Ausubel et al., 1987) and purified with DNA Clean-Up resin (Promega). Purified $#P-DNA (final concentration 10& c.p.m.\ml) was incubated with the nitrocellulose sheet for 1 h at 22 mC. The nitrocellulose sheet was then washed with 10 mM Tris-HCl, pH 6n7, 50 mM NaCl, 1 mM EDTA before being air-dried and subjected to autoradiography. After the DNAbinding assay, $#P-DNA was removed from the nitrocellulose by incubation in a solution containing DNase I. The same nitrocellulose sheet was then used for Western blot analysis.
Delivery of exogenous DNA into human cells by pseudocapsid particles. Procedures for packaging exogenous DNA into pseudocapsid particles were described by Forstova et al. (1995) . Briefly, 40 µg pseudocapsid protein was mixed with 3 µg pEGFP-C1 plasmid DNA (Clontech) in 150 mM NaCl, 10 mM Tris-HCl, pH 7n4, 0n01 mM CaCl # . The mixture was incubated for 10 min at 37 mC. Osmotic shock was achieved by dilution of the mixture with 350 µl distilled water and then the mixture was incubated for 20 min at 37 mC. DNase I (3 U, Promega) was added and the mixture was incubated for 20 min at 37 mC. Pseudocapsid particles were purified by 10-30 % sucrose gradient centrifugation for 40 min at 35 000 r.p.m. in a Beckman SW-41 Ti rotor. Fractions containing particles (monitored by HA activity) were collected and dialysed against 150 mM NaCl, 10 mM Tris-HCl, pH 7n4, 0n01 mM CaCl # . Capsid particles were concentrated by ultracentrifugation for 3 h at 35 000 r.p.m. and resuspended in 300 µl PBS.
To examine introduction of exogenous DNA into human 293 foetal kidney epithelial cells (ATCC CRL-1573) by pseudocapsids, cells were grown on coverslips in 35 mm dishes in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % foetal calf serum. The cells were washed with PBS and incubated with pseudocapsids containing pEGFP-C1 plasmid for 1 h at 37 mC. Dishes were agitated every 15 min. Complete DMEM medium was then added to the culture and the culture was incubated at 37 mC with 5 % CO # . After 48 h, the cells were mounted on slides and expression of fluorescent protein in the cells was observed under a UV microscope.
Results

Expression of JCV VP1 in E. coli cells
In this study, the JCV VP1 gene was removed from the prokaryotic expression plasmid pGEXJCV1 (Chang et al., 1996 a) and cloned into ∆pFlag for expression of full-length, non-fusion VP1 protein in E. coli JM109 cells. After IPTG induction, E. coli JM109 cells expressing JCV VP1 protein were harvested and lysed to obtain a total cell lysate. The recombinant cell lysate was analysed by SDS-PAGE (Fig. 1 a) and Western blot (Fig. 1 b) to verify that the VP1 protein was expressed by E. coli JM109 cells. The Western blot shows that VP1 protein was expressed in E. coli (Fig. 1 b, lane 2) .
HA assay of E. coli cell lysate containing JCV VP1
We have shown previously that JCV VP1 protein expressed in Sf9 insect cells was able to form capsid-like particles and (Chang et al., 1997) . In order to determine whether JCV VP1 forms a capsid-like structure in E. coli, an HA assay using O-type human red blood cells was performed. The results show that an E. coli JM109 cell lysate did not cause HA but that an E. coli cell lysate containing the expressed JCV VP1 (JM109\VP1) showed strong HA activity (Table 1) . To determine whether HA was caused specifically by VP1-containing capsids, an HA inhibition assay was performed. When a JM109\VP1 cell lysate was mixed with JCV-positive human serum prior to reacting with red blood cells, HA was completely abolished. In contrast, JCVnegative human serum did not inhibit HA (Table 1) . These results suggest that JCV VP1 forms capsid-like particles when expressed in E. coli cells.
Purification of capsid-like particles from E. coli
The positive result of the HA assay with the JM109\VP1 cell lysate implies that JCV VP1 can self-assemble to form a capsid-like structure in E. coli. We next performed CsCl density-gradient centrifugation to purify capsid particles. After density-gradient centrifugation of the cell lysate, each fraction Capsid-like particles were fractionated after CsCl density-gradient centrifugation and analysed for HA activity and buoyant density.
was analysed by HA assay and density determination. Two peaks of HA activity were found, at densities of 1n34 and 1n29 g\cm$ (Fig. 2) . Fractions 1-18 were further analysed by SDS-PAGE (Fig. 3 a) and Western blot (Fig. 3 b) . Fig. 3 (a) shows that JCV VP1 was purified to near-homogeneity by CsCl density-gradient centrifugation. Fractions 8 (density 1n34 g\cm$) and 14 (density 1n29 g\cm$) showed the greatest HA activities (Fig. 2) and contained the largest amount of VP1 protein (Fig. 3 a, b ; lanes 8 and 14).
Morphology of the purified particles
The VP1 capsid populations at densities of 1n34 g\cm$ (fractions 6-8) and 1n29 g\cm$ (fractions 14-16) were collected and viewed by electron microscopy. Fig. 4 (a) shows the morphology of the first population (density 1n34 g\cm$). The particles appeared almost homogeneous and had a virion-like structure. The diameter of the particles was approximately 45 nm. The second population (density 1n29 g\cm$), shown in Fig. 4 (b) , contained empty capsid-like particles with a diameter of 42 nm.
Nucleic acid extraction from virion-like particles
To determine whether cellular nucleic acids were packaged in the virion-like particles, the virion-like population at a density of 1n34 g\cm$ was treated with DNase I and RNase A to eliminate any residual cellular DNA and RNA which might have adhered to the exterior of the particles. Nuclease-treated particles were purified by CsCl gradient centrifugation and nucleic acid extraction was then performed. Phenol--chloroform-extracted nucleic acids from nuclease-treated particles were analysed by agarose gel electrophoresis. The extract was found to consist of a band near 20 kb and some bands smaller than 2 kb (Fig. 5, lane 1) . In order to distinguish DNA and RNA molecules contained within the particles, the extract was then treated with DNase I (Fig. 5 , lane 2), RNase A (Fig. 5, lane 3) or both DNase I and RNase A (Fig. 5, lane 4) . The results showed that the band of 20 kb consisted of DNA molecules and the smaller bands consisted of RNA molecules. When the empty capsid-like particles were treated with the same procedures, no nucleic acids were found (Fig. 5, lane 5) .
JCV VP1 binds DNA in a non-sequence-specific manner
The packaging of host DNA in VP1 capsid-like particles allowed further analysis of the DNA-binding activity and DNA-binding specificity of JCV VP1. VP1 protein expressed in E. coli was separated by SDS-PAGE, electro-transferred onto a nitrocellulose membrane and then hybridized with nicktranslated $#P-labelled JCV genomic DNA or plasmid DNA. JCV VP1 was able to bind JCV genomic DNA (Fig. 6 a, lane 3) and plasmid DNA (Fig. 6 b, lane 3) . Murine polyomavirus VP1 was used in the same study as a positive control (Fig. 6 a, b ; lanes 1), since polyomavirus VP1 has been reported to bind DNA . Fig. 6 (c) shows that murine polyomavirus VP1 (lane 1) and JCV VP1 protein (lane 3) were recognized by immunoblotting with rabbit anti-polyomavirus serum and rabbit anti-JCV VP1 serum, respectively. These results indicate that JCV VP1 had DNA-binding activity and that this binding was not sequence specific.
Delivery of exogenous DNA into human cells by pseudocapsid particles
To demonstrate gene delivery, purified pseudocapsid particles were used to encapsidate a fluorescent proteinexpressing plasmid (pEGFP-C1). DNA-packaging pseudocapsid particles were treated with DNase I to remove any attached DNA and subsequently purified by sucrose gradient centrifugation. After infection of human 293 foetal kidney epithelial cells with plasmid-packaging pseudocapsid particles, fluorescent protein expression was observed under a UV microscope. Fig. 7 (b) shows that pseudocapsid particles were able to deliver a reporter plasmid into human 293 cells and that the fluorescent reporter protein was expressed in these cells. A control experiment consisting of mock infection with pEGFP-C1 plasmid DNA in the absence of capsid protein was also performed on 293 cells. No fluorescent protein was expressed in these cells (Fig. 7 a) . These results indicate that pseudocapsids of human JCV are capable of delivering exogenous DNA into human foetal kidney epithelial cells.
Discussion
Three structural proteins, the major capsid protein, VP1, and the minor capsid proteins, VP2 and VP3, are required for polyomavirus virion assembly in the cell nucleus (Tooze, 1981) . Although it is known that infectious virion particles contain viral capsid proteins, viral DNA and host-contributed histones, little is known about the mechanism of virion assembly. This is the first report to show that the VP1 protein alone is able to form capsid-like particles when expressed in E. coli. The prokaryote-generated capsid-like particles can cause HA of human O-type red blood cells and this HA activity can be inhibited by JCV-positive human serum (Table 1) and rabbit anti-JCV VP1 antiserum (data not shown), indicating a native conformation. Previously, E. coli-expressed murine polyomavirus VP1 (Haynes et al., 1993 ; Salunke et al., 1986) and human papillomavirus major capsid protein L1 (Li et al., 1997) have been isolated as pentameric capsomeres. The pentameric polyomavirus VP1 (Haynes et al., 1993 ; Salunke et al., 1986) and papillomavirus L1 (Li et al., 1997) are able to form capsidlike structures in the presence of calcium ions or high concentrations of NaCl. In this study, we were able to isolate JCV VP1 as a capsid-like particle from an E. coli cell lysate, perhaps because of differences in the purification procedures used. The E. coli-expressed murine polyomavirus VP1 and human papillomavirus L1 were treated with polymin P to precipitate proteins and then resolubilized in a capsomere buffer containing a chelator (EDTA) and a reducing agent (2-mercaptoethanol) (Li et al., 1997 ; Salunke et al., 1986) . It is known that the combination of chelator and reducing agent can cause dissociation of polyomavirus capsids into a capsomere structure (Brady et al., 1977) . Furthermore, we reexamined the ability of murine polyomavirus VP1 to selfassemble when expressed in E. coli . A total E. coli cell lysate containing murine polyomavirus VP1 was able to cause HA, indicating that the murine polyomavirus VP1 can also self-assemble into a capsid-like structure (data not shown).
E. coli-expressed JCV VP1 was found to consist of two populations of capsid particles after CsCl density-gradient centrifugation (Fig. 2) . The first population was found in a fraction with a buoyant density of 1n34 g\cm$, which is slightly higher than that of virion particles propagated in vivo (Brady et al., 1977) . Electron microscopy revealed that the morphology of the particles in the first population resembled a virion-like structure (Fig. 4 a) . Subsequent extraction of virion-like particles demonstrated that DNA and RNA molecules were encapsidated in the particles (Fig. 5) . Attachment of nucleic acids to the capsid surface appears to be unlikely in this case, since the same amount of an extract containing empty capsid particles treated with DNase and RNase did not yield any nucleic acid after extraction (Fig. 5, lane 5) . DNA encapsidation by murine polyomavirus VP1 (Gillock et al., 1997) and monkey BLPV VP1 (Pawlita et al., 1996) when expressed in insect cells has previously been reported. However, RNA encapsidation in polyomavirus particles has not been reported, even in virions propagated in vivo. This finding leads us to speculate that chaperone proteins may play a role in preventing VP1 from interacting with host RNA in eukaryotic expression systems (Cripe et al., 1995) . Encapsidated RNA molecules might be responsible for the higher buoyant density of the JCV virion-like particles when purified from E. coli.
The DNA-binding activity of viral capsid proteins may be involved in virion assembly. Previous studies have shown that VP1 is the only structural protein of murine polyomavirus that has DNA-binding activity . All three structural proteins, VP1 (Soussi, 1986) and VP2\3 (Clever et al., 1992) , of SV40 have been shown to exhibit DNA-binding activity. More recently, baculovirusexpressed murine polyomavirus VP1 was found to selfassemble and package 5 kbp DNA molecules in insect cells (Gillock et al., 1997) . Pawlita et al. (1996) showed that DNA fragments of 4n5 kbp and less than 0n6 kbp were encapsidated in virus-like particles when BLPV VP1 was expressed in insect cells. The present results demonstrate that JCV VP1 has DNAbinding (Fig. 6 ) and DNA-encapsidation (Fig. 5) activities. The encapsidated 20 kbp DNA is presumably contributed by E. coli, since the exogenous plasmid bearing the VP1 DNA is only 6 kbp in length. The size of DNA molecules packaged in viral particles after self-assembly in insect cells seems to vary. Sandalon et al. (1997) showed that the capsid-like particles formed by SV40 VP1 expressed in insect cells can package various lengths of DNA in vitro, although the viral genome is about 5 kbp. One possible explanation is that eukaryotic DNA may associate with host histone proteins to form a minichromosome conformation. In contrast, higher molecular mass prokaryotic DNA does not associate with histone proteins, resulting in a more compact conformation for accommodation in capsid-like particles.
The nuclear localization signal (NLS) and DNA-binding domain of murine polyomavirus and SV40 VP1 protein are located in the first 12 N-terminal amino acids (Chang et al., 1992 Ishii et al., 1996 ; . The amino acid sequence of JCV VP1 is closely related to those of murine polyomavirus and SV40 VP1. Therefore, it is reasonable to predict that the NLS and DNA-binding domain of JCV VP1 may also be located at the N terminus in a positively charged amino acid stretch (Met"-Ala-Pro-Thr-Lys-Arg-Lys-Gly-Glu-Arg-Lys-Asp"#). It will be interesting to find out whether the DNA-binding domain and the DNA-encapsidation signal are located in the same region of VP1. The prokaryotic expression system presented in this study may make it possible to answer this question. In contrast, it seems that investigation of the DNA-encapsidation signal would be difficult in a eukaryotic expression system, since mutation of the NLS might abolish nuclear translocation of VP1 protein, with the result that subsequent DNA-protein interactions in the nucleus would not occur. The virus assembly mechanisms involving interactions between VP1, VP2, VP3 and DNA could also be analysed by using a prokaryotic assembly system.
The capability of recombinant polyomavirus pseudocapsids to serve as a gene transfer vector for gene therapy purposes has recently been investigated. Murine polyomavirus VP1 is able to self-assemble into a capsid-like particle when expressed in insect cells (Forstova et al., 1993 ; Gillock et al., 1997 ; Montross et al., 1991) . Forstova et al. (1995) demonstrated that murine polyomavirus VP1 pseudocapsids generated from a recombinant baculovirus are able to transfer heterologous DNA efficiently into mammalian cells. More recently, SV40 pseudovirions self-assembled in insect cells have also been shown to be able to introduce foreign genes into mammalian cells (Sandalon et al., 1997) . The current study demonstrates that human JCV VP1 is able to form pseudovirion and pseudocapsid particles when expressed in E. coli. These JCV pseudocapsids were able to package exogenous DNA in vitro and to deliver the DNA into human cells. This may be important for future applications of human gene therapy with JCV pseudocapsids instead of murine polyomavirus or SV40 capsids. In addition, DNA encapsidation by JCV capsids in E. coli may provide an alternative approach for packaging genes of interest directly within the cells.
